Author: openjargon

There are moments in the market where a high-quality company quietly falls out of favour.

Not because its long-term story has disappeared, but because short-term issues start to dominate the narrative.

That is how I see CSL Ltd (ASX: CSL) right now.

After falling more than 40% over the past year, this is no longer a biotechnology stock riding momentum. It is one that is being questioned. And for me, that is exactly when it becomes interesting.

A weaker period, but not a broken business

There is no denying that CSL has had a difficult stretch.

Its latest half-year result showed softer performance, with underlying profit declining and revenue slightly lower, impacted by policy changes, restructuring costs, and impairments.

On the surface, that explains why the share price has struggled.

But when I look a bit deeper, I do not see a business in decline. I see one going through a reset.

Management has been very clear that it is not satisfied with recent performance and is actively implementing changes to improve growth and efficiency.

That matters. Because I think this is less about structural weakness and more about execution, transition, and short-term disruption.

The turnaround is already underway

What stands out to me most is that CSL is not standing still.

The company is progressing a transformation program focused on simplifying operations, reducing costs, and investing in future growth. It has already achieved a significant portion of its targeted cost savings and expects meaningful efficiency gains over the coming years.

At the same time, it is continuing to invest in its pipeline.

For example, its licensing agreement with Eli Lilly and Co (NYSE: LLY) for clazakizumab highlights ongoing efforts to develop new therapies and expand its product offering.

This is what I would expect from a global healthcare leader.

It is addressing current challenges while still positioning itself for long-term growth.

Why the risk-reward looks attractive for CSL shares

When a stock falls 40% or more, expectations tend to reset.

That can create an interesting setup.

If things continue to deteriorate, the downside may be more limited if expectations are already low. But if the business stabilises and begins to improve, the upside can be significant.

CSL still operates in areas like plasma therapies, vaccines, and specialty pharmaceuticals. These are not short-term trends. They are long-term healthcare needs.

The company is also guiding for a stronger second half, supported by key therapies and newly launched products.

That tells me the growth story has not disappeared.

It has just become less linear.

This is where patience comes in

I do not expect CSL and its shares to bounce back overnight.

Turnarounds take time. Execution matters. And there may still be volatility ahead.

But when I look out over the next five to ten years, I think the current share price starts to look far more interesting than it did a year ago.

This is a business with global scale, deep expertise, and products that address serious medical needs.

Those characteristics do not disappear because of one difficult year.

Foolish takeaway

I think CSL shares are entering a phase where long-term investors should start paying close attention.

The past year has been disappointing. There is no getting around that. But with the share price down more than 40%, a transformation program underway, and growth expected to improve, I believe the risk-reward has shifted.

For me, this is exactly the type of situation where it can make sense to start leaning in.

The post Is it time to get greedy with CSL shares? appeared first on The Motley Fool Australia.

More reading

• Why I’d buy dirt-cheap ASX shares now and aim to hold them for a decade
• Is it too late to start investing in ASX shares in your 40s?
• Where to invest $10,000 in ASX 200 shares this April
• How I’d aim to build a $100,000 ASX share portfolio starting at zero
• Building an ASX share portfolio from scratch? Here’s my game plan

Motley Fool contributor Grace Alvino has positions in CSL. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Guzman Y Gomez (ASX: GYG) shares are sinking today.

Shares in the S&P/ASX 200 Index (ASX: XJO) Mexican fast food restaurant chain closed yesterday trading for $16.00. In early afternoon trade on Tuesday, shares are changing hands for $15.86 apiece, down 0.9%.

For some context, the ASX 200 is up 0.6% at this same time.

Today’s underperformance is par for the course for the struggling restaurant owner and operator.

Indeed, now down 50.8% in 12 months, Guzman Y Gomez shares just fell to new all-time lows (should the price at time of writing be maintained until close).

Even stockholders who managed to take part in the initial public offering (IPO) on 20 June 2024 are in the red now. IPO investors were able to buy shares for $22.00 each. This saw them book a one-day gain of 36.4%, with the ASX 200 stock ending its first day of trading at $30.00 a share.

But after then rising to $43.35 a share by 6 December 2024, it’s been mostly a downhill ride for stockholders since then.

Taking just a little bit of the sting from those losses, the ASX 200 stock paid two fully franked dividends over the past year, totalling 20 cents a share.

So, with shares having halved in a year, and down by 63.4% since the December 2024 record closing high, is the Mexican restaurant chain finally selling for a bargain?

Are Guzman Y Gomez shares now on sale?

Catapult Wealth’s Blake Halligan recently ran his slide rule over the company (courtesy of The Bull).

“GYG is a Mexican themed restaurant chain,” Halligan said.

Pointing to the past year’s painful share price decline, he noted, “GYG shares have fallen from $31 on March 31, 2025 to trade at $16.81 on March 26, 2026.”

Despite that big retrace, and the company’s relatively strong H1 FY 2026 performance in its Australian market, Halligan has a sell recommendation on Guzman Y Gomez shares.

“Although network sales grew 18% to $682 million in the first half of fiscal year 2026, several metrics signal caution,” he said.

According to Halligan:

Segment underlying EBITDA [earnings before interest, taxes, depreciation and amortisation] in the United States posted a loss of $8.3 million. The stock continues to trade on high price/earnings multiples.

The ASX 200 fast food stock released its half year results on 20 February. And with investors apparently more concerned over potential headwinds in the US markets than the growth posted in Australia, Guzman Y Gomez shares closed down 13.9% on the day the results were posted.

Summing up his sell recommendation, Halligan concluded, “In our view, execution risks are rising and margins are under pressure. Investors may find better opportunities by re-allocating funds to alternative investments.”

The post Guzman Y Gomez shares just sank to new all-time lows. Time to buy? appeared first on The Motley Fool Australia.

More reading

• 2 top ASX shares to buy and hold for the next decade
• Buy, hold, sell: BHP, Guzman Y Gomez, and Pro Medicus shares
• These are the 10 most shorted ASX shares
• A rare buying opportunity for this ASX 200 stock as it rebounds from a historic low
• 4 ASX All Ords shares at 52-week lows: Buy, hold, or sell?

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The S&P/ASX 200 Index (ASX: XJO) is having a better day on Tuesday. In afternoon trade, the benchmark index is up 0.9% to 8,537.9 points.

Four ASX shares that are rising more than most today are listed below. Here’s why they are climbing:

Challenger Ltd (ASX: CGF)

The Challenger share price is up 3.5% to $8.41. This morning, the annuities company welcomed APRA’s announcement on the final changes to capital standard settings for providers of longevity products. It believes these are “an important step in developing Australia’s retirement income market and will support greater take up of lifetime income products as an increasing number of Australians retire every year.” Challenger is working through the details of the changes and plans to provide an update at its investor day event in May.

Magellan Financial Group Ltd (ASX: MFG)

The Magellan share price is up over 2% to $9.76. This morning, the fund manager announced that it raised $20 million from its share purchase plan (SPP). The company advised that the SPP was significantly oversubscribed. It received valid applications totalling $129.4 million from 5,195 eligible shareholders. Approximately 2,366,548 new Magellan shares will be issued at $8.45 per share. The new shares will hit the ASX boards on 2 April.

Northern Star Resources Ltd (ASX: NST)

The Northern Star share price is up 4.5% to $20.39. This appears to have been driven by a broker note out of UBS. This morning, the broker upgraded Northern Star’s shares to a buy rating (from sell) with a trimmed price target of $24.70 (from $28.00). UBS made the move on valuation grounds following a significant share price decline since the release of a disappointing operational update. While the broker feels that near-term market estimates are still optimistic, it sees value in Northern Star’s shares at current levels.

West African Resources Ltd (ASX: WAF)

The West African Resources share price is up 4% to $3.18. This morning, the gold miner released its FY 2026 guidance. It is targeting up to 490,000 ounces at an all-in sustaining cost (AISC) under US$1,900 per ounce. It also laid out its plans for the next 10 years, which will see it aim to average production of 533,000 ounces per annum. West African’s executive chair and CEO, Richard Hyde, commented: “WAF’s updated 10-year production outlook forecasts the production of 5.3 million ounces of gold over the next decade, with production peaking in 2030 at 596,000 ounces. Our unhedged Mineral Resources now stand at 13.6 million ounces of gold, while Ore Reserves total 7.0 million ounces.”

The post Why Challenger, Magellan, Northern Star, and West African Resources shares are storming higher appeared first on The Motley Fool Australia.

More reading

• Why Magellan shares are rising again after its $20 million raise was swamped
• Down 38% in March, should you buy the dip on Northern Star shares?
• Challenger shares in focus as APRA unveils new capital rules
• Guess which ASX 200 gold stock is lifting off today on record breaking news
• Magellan Financial Group shares in focus after $20m share plan hits target

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Challenger. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

S&P/ASX 200 Energy Index (ASX: XEJ) shares are up 0.4% while the benchmark S&P/ASX 200 Index (ASX: XJO) is up 0.7% on Tuesday.

ASX 200 energy shares have skyrocketed 14% over the past month due to a huge spike in oil and gas prices caused by the conflict in Iran.

The conflict has effectively closed the Strait of Hormuz, through which about 20% of the world’s oil and gas supplies are shipped.

Some Middle East oil and gas producers have been forced to cease production as storage tanks fill up and tankers in the Strait sit still.

After Yemen joined the fighting over the weekend, passage of oil and gas via the Red Sea and the Strait of Bab al-Mandeb is also at risk.

The world is grappling with the ensuing oil shock, which has sent Brent Crude 39% higher over 30 days to US$107.70 per barrel today.

Gas prices are also substantially higher. European gas prices are up 24%, UK gas is up 21%, and German gas is up 23% over 30 days.

The thermal coal price is also 12% higher over the month as power plants switch from gas to coal.

In the latest developments, US President Donald Trump threatened to hit Iran’s electricity plants, oil facilities, and desalination plants if the Strait of Hormuz is not reopened.

Trading Economics analysts said the threat overshadowed Trump’s earlier comments that negotiations with Iran were progressing well.

The analysts said:

Iran-backed Houthis in Yemen also entered the conflict by targeting Israel over the weekend, while Tehran is reportedly urging militant groups to prepare for a renewed campaign to disrupt Red Sea shipping.

Such developments risk further tightening energy flows from the Middle East, as two of the main strategic waterways in the world for trade and energy supplies could potentially be cut off.

With ASX 200 energy shares on fire right now, here are four stocks that the experts rate a buy.

Santos Ltd (ASX: STO) 

The Santos share price is $8.01, down 0.3% today and up 11.4% over the past month.

Last week, UBS commenced coverage with a buy rating on Santos shares.

The broker has a 12-month price target of $8.80 on this ASX 200 energy share.

Karoon Energy Ltd (ASX: KAR)

The Karoon Energy share price is steady on Tuesday at $2.14.

Karoon Energy shares have soared 20.2% over the past month.

Earlier this month, Jarden reiterated its buy rating on this ASX 200 energy share.

The broker lifted its 12-month target from $1.57 to $2.47.

Whitehaven Coal Ltd (ASX: WHC)

The Whitehaven share price is $9.62, down 2.2% today and up 21.2% over the month.

Last week, UBS reiterated its buy rating and lifted its price target on this ASX 200 coal share significantly.

UBS moved its 12-month target from $7.90 to $10.10.

Viva Energy Group Ltd (ASX: VEA)

The Viva Energy share price is $2.59, up 2.4% on Tuesday and up 42% over the past month.

Last week, RBC Capital upgraded this ASX 200 energy share to a buy rating.

The broker also lifted its 12-month price target from $1.90 to $2.50.

The post 4 ASX 200 energy shares rated buys appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Tuesday
• Here are the top 10 ASX 200 shares today
• 5 things to watch on the ASX 200 on Monday
• Here are the top 10 ASX 200 shares today
• Why New Hope, Yancoal and Whitehaven shares are storming higher on Friday

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Analysts have been busy running the rule over several ASX shares this week.

Let’s see what they are saying about these shares, courtesy of The Bull. Here’s what you need to know:

BHP Group Ltd (ASX: BHP)

The team at MPC Markets has named this mining giant as a hold this week.

While it is a fan of BHP, it appears to be waiting for a pullback before recommending its shares as a buy. It said:

The global miner delivered a strong half year result in fiscal year 2026. Copper delivered the majority of earnings for the first time in the company’s modern history. The dividend was above expectations. The balance sheet is in good shape. The conflict in Iran has rattled commodity markets, and BHP shares have fallen heavily.

Most of BHP’s output goes to Asia, not through the Strait of Hormuz. The market is selling the ticker, not the fundamentals. We suggest adding on weakness, and holding for an upgrade when the conflict ends.

Commonwealth Bank of Australia (ASX: CBA)

Over at Sanlam Private Wealth, it has named this banking giant as a sell this week.

Although CBA is a high-quality bank, it isn’t a fan of its valuation. This is particularly the case given how it believes rising interest rates could slow the global economy and credit growth. It explains:

The bank is a quality company and a staple in investor portfolios. It has established a strong track record of performance over many years. The company delivered a 5 per cent increase in statutory net profit after tax in the first half of fiscal year 2026.

However, the dividend yield was trading below 3 per cent on March 26, so better income is available elsewhere. The conflict in Iran suggests a possibly slowing global economy likely to impact credit growth in Australia’s higher interest rate environment. CBA is trading at a premium to peers, so it may be time to consider reducing exposure in this volatile environment.

Pro Medicus Ltd (ASX: PME)

One ASX share that MPC Markets is positive on is Pro Medicus. It has named the health imaging technology company’s shares as a buy.

MPC Markets thinks investors should be buying the dip after recent share price weakness. It said:

The company provides medical imaging software and services to hospitals and healthcare groups across the world. Its software has quietly become the dominant choice across some of the largest hospital networks in the United States. The product is faster, more scalable and modern than what its competitors offer. Artificial intelligence is built in, so it complements the business.

The share price plunge has been driven by broad technology sentiment as opposed to issues with the business. Earnings are still growing and the company still wins major new hospital contracts. In our view, the market has handed investors an appealing entry point into one of the best software businesses on the ASX. We retain our buy recommendation.

The post Buy, hold, sell: BHP, CBA, and Pro Medicus shares appeared first on The Motley Fool Australia.

More reading

• 3 ASX 200 healthcare shares at multi-year lows
• ASX 200 mining shares ride a rollercoaster in March quarter
• BHP shares: 3 reasons to buy and 3 reasons to sell
• 5 of the best ASX ETFs to buy in April
• ASX share market sell off: Buy in the dip or stay on the sidelines?

Motley Fool contributor James Mickleboro has positions in Pro Medicus. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended BHP Group and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Northern Star Resources Ltd (ASX: NST) shares are pushing higher today.

Shares in the S&P/ASX 200 Index (ASX: XJO) gold stock closed yesterday trading for $19.51. As we head into the Tuesday lunch hour, shares are changing hands for $19.56 apiece, up 0.3%.

For some context, the ASX 200 is down 0.5% at this same time.

Northern Star shares remain up 6.8% over 12 months – not including the two partly franked dividends totalling 55 cents per share – despite the horror month the miner just experienced.

Hit with stiff headwinds from a fast-falling gold price and negative investor reaction to its decreased FY 2026 production guidance, shares in the ASX 200 gold stock are down a steep 38.4% since market close on 2 March.

That compares to an 8.4% decline in the ASX 200 and a 30.0% drop in the S&P/ASX All Ordinaries Gold Index (ASX: XGD) over this period.

Which brings us back to our headline question.

After plunging more than 38% in a month, is the Aussie gold mining giant now a bargain buy?

Should you buy Northern Star shares today?

MPC Markets’ Mark Gardner recently analysed the outlook for the ASX 200 gold miner (courtesy of The Bull).

“The gold company has been punished for downgrading gold production,” he said. “Mechanical and equipment issues at its flagship Kalgoorlie operation have been frustrating, and the market has lost patience.”

Indeed, Northern Star shares closed down 18.8% on 13 March after miner announced that, due to the issues Gardner mentions above, it now expects FY 2026 gold production of at least 1.50 million ounces. That was down from full year guidance of 1.60 million to 1.70 million ounces of gold reported on 2 January, which was already revised downwards from earlier guidance of 1.70 to 1.85 million ounces.

But Gardner notes that the long-term outlook for investing in the ASX 200 gold stock remains in place.

“However, Northern Star still owns one of the best gold assets in the world and its long-term reserve base is intact,” he said.

Gardner also pointed to the impact of the Iran war as potentially offering a good buying opportunity for Northern Star shares.

“The conflict in Iran has also generated indiscriminate selling in gold miners that history tends to show as a buying opportunity,” he noted.

Amid the prospect of rising interest rates, and as investors the world over have tapped into liquid assets to meet their financial obligations, the gold price has plunged 15% since 2 March, currently trading for US$4,518 per ounce.

Commenting on his current hold recommendation on Northern Star, Gardner concluded, “Operational problems are temporary, and we expect the gold price to improve moving forward.”

The post Down 38% in March, should you buy the dip on Northern Star shares? appeared first on The Motley Fool Australia.

More reading

• Why Challenger, Magellan, Northern Star, and West African Resources shares are storming higher
• Buy, hold, sell: Northern Star, Telix, and Virgin Australia shares
• Here are the top 10 ASX 200 shares today
• 5 things to watch on the ASX 200 on Monday
• ASX 200 mining shares rebound after March sell-off creates opportunities

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Koala Company Ltd (ASX: KOA) has listed at a healthy premium to its initial public offer price in an auspicious start to its life as a publicly traded company.

The furniture company raised $20 million via the issue of new shares, while existing shareholders sold down $48.1 million worth of stock under the ASX listing.

Early share jump

The company’s shares were priced at $3.40, however in early trade were changing hands for $3.75, up 10.3%.

On listing, the top 20 shareholders, which include several institutions, hold 97.48% of the shares on issue.

Koala also issued an interim report on its listing debut, showing that it made a profit of $5.37 million for the first half, up from a loss of $2.28 million for the previous corresponding period.

The company said it had enjoyed a “strong and growing average selling price and improved margins during the period”.

Koala said in its initial public offer prospectus that it was founded in 2015 and experienced early success selling its Koala mattress, “quickly becoming a leading Australian mattress brand”.

The company launched in Japan in 2017, and in 2018, launched its first sofa product in Australia, with that range also subsequently expanding to Japan.

The prospectus says further:

In November 2023, Koala launched in the US market with a targeted expansion and disciplined investment, delivering significant early growth. In 2025, Koala expanded its international footprint further with the launch into the UK market.

Chair Michael Gordon said the company was well-placed for growth.

As a furniture company, Koala is exposed to the global furniture market, which benefits from tailwinds including the growth of e‑commerce, increased time spent at home due to the shift to remote work, a desire to maximise the utilisation of living spaces, a growing emphasis on convenience, premiumisation, and the demand for more sustainable products. The business has a significant opportunity before it to grow in Koala’s established markets, scale its presence in newer markets and enter into additional markets over time to grow the business. The global furniture market has shown relatively steady and consistent rates of moderate growth in Koala’s key categories. Koala’s ability to enter new markets and scale is driven by its capital‑light business model and in‑house innovation capabilities, which enables the team to promptly adapt to changing consumer needs and market trends.

Further growth tipped

Koala is forecasting FY26 revenue of $332 million and net profit of $12.3 million.

Koala’s prospectus said the company would be valued at $305.3 million on listing at the $3.40 offer price.

The post The ASX’s newest entrant is off to a strong start appeared first on The Motley Fool Australia.

More reading

• Why Magellan shares are rising again after its $20 million raise was swamped
• After a major resource upgrade, how undervalued are Greatland shares looking?
• Is it time to get greedy with CSL shares?
• Guzman Y Gomez shares just sank to new all-time lows. Time to buy?
• Why Challenger, Magellan, Northern Star, and West African Resources shares are storming higher

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Shares of Tyro Payments Ltd (ASX: TYR) are pushing higher on Tuesday.

This comes after the payments company welcomed the Reserve Bank of Australia (RBA)’s final reforms on card surcharging and merchant payment costs.

In midday trade, the Tyro share price is up 4% to 78 cents, after climbing as high as 80 cents before some profit-taking trimmed the gain.

The latest move follows an announcement that could strengthen the company’s longer-term competitive position.

Why investors are cheering today

According to the release, Tyro welcomed the RBA’s final reforms on card surcharging, interchange fees, and fee transparency across the payments sector.

The changes include a ban on surcharging for EFTPOS, Visa, and Mastercard transactions from 1 October 2026, alongside lower interchange caps and new disclosure requirements for larger payment providers from April 2027.

The RBA estimates the changes could save consumers and businesses a combined $2.5 billion each year.

Tyro said the reforms are in line with its expectations and will not affect its near-term financial guidance.

That is likely one of the main reasons the share price is moving higher, with investors viewing the regulatory changes as encouraging stronger competition across the merchant acquiring market.

Chief Executive Nigel Lee said the reforms represent “a win for consumers through lower payments costs, and a win for Australian small businesses through simpler and more transparent pricing”.

He added that the changes also mark a structural shift away from surcharge-led and opaque bundled pricing, which could encourage merchants to reassess their payment providers.

Tyro already operates with clearer transaction pricing and vertical-specific payment solutions.

The company has 76,000 merchants on its platform and may be well placed if smaller businesses begin reviewing incumbent providers under the new framework.

Clear rollout dates support Tyro’s outlook

Another supportive part of the update was the clear implementation timetable.

The RBA has confirmed that the surcharge ban and domestic interchange fee reductions will both begin on 1 October 2026, while the cap on foreign-issued cards and extra disclosure requirements for large acquirers will start from 1 April 2027.

That longer runway gives payment providers time to adapt systems, merchant communication, and pricing structures without disrupting current earnings expectations.

Lee said Tyro already operates cost-plus and card-based pricing models that align with the transparency objectives, adding that its systems and operational capability are already set up to support the reforms.

Despite today’s share price rise, the stock is still down by more than 20% in 2026.

The post This ASX payments stock jumped after a key RBA decision appeared first on The Motley Fool Australia.

More reading

• This ASX gold explorer could more than double according to the team at Canaccord Genuity
• 3 ASX 200 healthcare shares at multi-year lows
• Why I’d buy dirt-cheap ASX shares now and aim to hold them for a decade
• ASX 200 mining shares ride a rollercoaster in March quarter
• EOS shares rebound after a surprise twist in its South Korean laser deal

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Tyro Payments. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Saturn Metals Ltd (ASX: STN) is an aspiring gold producer that the team at Canaccord Genuity has just started covering, and which they like the look of.

So what’s piqued their interest?

Derisking underway

Let’s look at Saturn Metals’ most recent ASX release for a start.

The company said on March 26 that it had appointed engineering and consulting firm Ausenco to conduct a definitive feasibility study (DFS) for its flagship Apollo Hill gold project in Western Australia.

The DFS will be based on a new mineral resource estimate, which the company said was due for completion in the second quarter of this calendar year.

The DFS would also refine the mining, metallurgy, and engineering designs included in Saturn’s prefeasibility study, which it put out in December.

The DFS is scheduled for completion during the fourth quarter of this calendar year, the company said.

Saturn Managing Director Ian Bamborough said last weeK:

We are pleased to award the contract for the Apollo Hill DFS to a company of Ausenco’s calibre and capability. Importantly, Ausenco has a strong track record of success in developing first-class heap leach projects across the globe, which will be a real asset for Saturn. A solid grounding in the Australian engineering and construction environment makes Ausenco an ideal business partner as we take the next important step in advancing the development of a large-scale, long-life gold project at Apollo Hill.

Shares looking cheap

Canaccord said in its research note to clients this week that since listing in 2018, Saturn had scaled and derisked the Apollo Hill project, “defining a bulk-tonnage, low-strip, single open pit enabled by heap leach, its key differentiator among Australian developers”.

Canaccord added:

Heap leaching is re-emerging in Australia as a disciplined, mainstream development pathway rather than a low-cost fallback, driven by three key shifts: decades of global operating experience have de-risked design, agglomeration, stacking and monitoring; WA offers ideal conditions with low seismicity, flat terrain, arid climate, strong regulation and deep technical capability; and modern workflows assess heap leach viability early, using detailed mineralogy, large-scale column test work and improved geosynthetics to define realistic recoveries and performance.

Canaccord has modelled a mine with a 14-year mine life, mining 10 million tonnes of ore per year, using the mineral resource estimate in the prefeasibility study.

They also note that the company is undertaking an aggressive drilling campaign both across the main deposit and more broadly.

Canaccord has a $1 price target on Saturn shares compared with 44 cents currently.

Saturn Metals is currently valued at $221.5 million.

The post This ASX gold explorer could more than double according to the team at Canaccord Genuity appeared first on The Motley Fool Australia.

More reading

• This ASX payments stock jumped after a key RBA decision
• 3 ASX 200 healthcare shares at multi-year lows
• Why I’d buy dirt-cheap ASX shares now and aim to hold them for a decade
• ASX 200 mining shares ride a rollercoaster in March quarter
• EOS shares rebound after a surprise twist in its South Korean laser deal

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

S&P/ASX 200 Health Care Index (ASX: XHJ) shares are 1.2% higher on Tuesday but down 17% over the first quarter of 2026.

Healthcare shares are facing many headwinds, as portfolio managers Joe Koh and Elan Miller from Blackwattle explain:

The sector as a whole has faced multiple headwinds, including currency and tariffs for the large multinationals and labour and cost pressures for the domestic players.

Today, eight of the 10 largest ASX 200 healthcare shares are trading at or close to multi-year or 52-week lows.

Does this present a buying opportunity?

Let’s see what the experts say about three of these ASX 200 healthcare shares.

Sonic Healthcare Ltd (ASX: SHL)

The Sonic Healthcare share price fell to a decade-low of $19.57 last week.

This ASX 200 healthcare share has fallen 9.7% in the year to date (YTD) and 21.3% over the past year.

Last week, Ord Minnett issued a new note on Sonic Healthcare shares.

The broker maintained its hold rating with an unchanged target of $24.

Ord Minnett commented:

Ord Minnett finds it difficult to be constructive on Sonic given its inability to generate meaningful organic growth even after $3.3 billion of acquisitions over the past seven years.

There are undoubtedly some benefits from M&A, but other factors, such as price cuts and customer quotas specific to heathcare in its various markets, along with run-of-the mill costs such as wages and rents, appear to have constrained any meaningful earnings growth.

This view leads us to maintain our Hold recommendation despite the apparent value on offer.

Cochlear Ltd (ASX: COH)

The Cochlear share price tumbled to a six-year low of $160 last week.

This ASX 200 healthcare share has fallen 36.1% YTD and 36.4% over the past year.

Wilsons says Cochlear shares are trading at “a compelling entry point”.

The broker commented:

Cochlear trades on a forward P/E multiple of ~26x, representing a >10 year low and a material discount to its 10-year average of ~42x.

We view this as a compelling entry point for a high-quality business ahead of accelerating earnings growth.

Wilsons expects the launch of Cochlear’s Nucleus Nexa product to drive sales growth over the medium term.

Cochlear is approaching an inflection point in its earnings growth trajectory, supported by the ongoing global rollout of Nucleus Nexa (approved in mid-2025), which is its most significant product launch in over two decades.

Nexa’s upgradeable firmware architecture represents a step-change in implant technology, enabling ongoing improvements in sound processing, connectivity and battery life via its Smart Sync app.

The rollout over the next few years should support ~10% CI unit growth over the medium term, with potential upside toward the mid-teens, while recurring implant upgrades will extend the Nexa’s product cycle, supporting a longer duration of growth.

Pro Medicus Ltd (ASX: PME)

The Pro Medicus share price crumbled to a two-year low of $107.75 late last month.

This ASX 200 healthcare share has fallen 49.3% YTD and 43.5% over the past year.

Pro Medicus shares are experiencing a period of correction after a ripsnorting two-year run through to mid 2025.

The Pro Medicus share price hit a record $336 per share in July last year.

Bell Potter has a buy rating and $240 price target on Pro Medicus shares.

The broker explains:

The company continues to announce new contract wins on a regular basis as the drivers of interest in its product offering remain firmly in place. The entire radiology industry is headed to cloud based (off premises) archiving. Put simply, the Visage 7 viewer, Workflow and Archive are the fastest and most advanced tools for the retrieval and viewing of large radiology files.

The platform is immensely scalable and relatively easily installed, providing it with a sustainable competitive advantage over the likes of peers Intelerad, Sectra, Philips and GE Healthcare. The company is conservatively managed and well owned by large institutional investors while the two founders continue to have a controlling stake.

The post 3 ASX 200 healthcare shares at multi-year lows appeared first on The Motley Fool Australia.

More reading

• Why I’d buy dirt-cheap ASX shares now and aim to hold them for a decade
• 3 reliable ASX dividend shares for set-and-forget investing
• Buy, hold, sell: BHP, Guzman Y Gomez, and Pro Medicus shares
• 3 reasons to buy Pro Medicus shares today
• 3 ASX 200 shares that could beat the market over the next 10 years

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Cochlear, Pro Medicus, and Sonic Healthcare. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.